S. Pallanti - Vol. 10, December 2004, Issue 4
Testo Bibliografia Summary Indice
Serotonina: il presente e il futuro
Serotonin: present and future
1 Duxon MS, Flanigan TP, Reawley AC, Baxter GS, Blackburn TP, Fone KCF. Evidence for expression of the 5HT2B receptor protein in the rat CNS. Neuroscience (Oxford) 1997;76:32-9.
2 Kennet GA, Aiswworth K, Trail B, Blackburn TP. BW 723C86, a 5HT2B receptor antagonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 1997;36:23-39.
3 Millan MJ, Dekeyne A, Gobert A. Serotonin 5HT2C receptors tonically inhibit Dopamine (DA) and Noradrenaline (NA) but not SHT, release in the frontal cortex in vivo. Neuropharmacology 1998;37:953-5.
4 Jorgensen H, Knigge U, Kiaer A, Warberg J. Adrenocorticotropic hormone secretion in rats induced by stimulation with serotonergic compounds. J Neuroendocrinol 1999;11:283-90.
5 Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 1999;65:1217-35.
6 Boess FG, Martin IL. Molecular Biology of 5HT receptors. Neuropharmacology 1994;33:275-317.
7 Laporte AM, Kidd EJ, Verge D, Gozlan H, Hamon M. Autoradiographic mapping of central 5HT3 receptors. In: Hamon M, ed. Central and peripheral 5HT3 receptors. London, UK: Academic press 1992, pp 15787.
8 De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptors subtypes. Drugs 2001;61:317-32.
9 Barnes JM, Barnes NM. Neurochemical consequences following pharmachological manipulation of central 5HT4 receptors. In: Eglen RM, ed. 5HT4 receptors brain periphery. Berlin: Springer 1998, pp. 10326.
10 Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-95.
11 Malison RT, Price LH, Berman K, van Dyck CH, Pelton GH, Carpenter L, et al. Reduced brain serotonin transporter availability in major depression as measured by [1231]2 betacarbomethoxy3 beta(4iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-8.
12 Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, et al. A serotonin transporter gene promoter polymorphism (5HTTLPR) and prefrontal cortical hinding in major depression and suicide. Arch Gen Psychiatry 2000;57:729-38.
13 Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and impulse control disorders. J Neuropsychiatry Clin Neurosci 1993;5:9-17.
14 Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59(Suppl 14):11-4.
15 Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion induced depressive relapse. Arch Gen Psychiatry 1997;54:364-74.
16 Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998;51:215-35.
17 Becker G, Elerg D, Lesch KP, Becker T. Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 2001;4:21-31.
18 Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-80.
19 Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998;44:534-49.
20 Handley SL. 5Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 1995;66:103-48.
21 Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF. Anxiolytic like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 1994;49:281-5.
22 Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin 1A receptor. Proc Natl Acad Sci USA 1998;95:1073-49.
23 Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al. Serotonin receptor 1A knockout: an animal model of anxietyrelated disorder. Proc Natl Acad Sci USA 1998;95:14476-81.
24 Lesch KP. Serotonergic gene expression and depression: implications for developing novel antidepressants. J Affect Disord 2001;62:57-76.
25 Iny LJ, Pecknold J, SuranyiCadotte BE, Bernier B, Luthe L, Nair NP, et al. Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry 1994;36:281-91.
26 Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5.
27 Zohar J, Insel TR, ZoharKadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988;45:167-72.
28 Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, et al. Cerebral metabolism in major depression and obsessive compulsive disorder occurring separately and concurrently. Biol Psychiatry 2001;50:159-70.
29 Khang DH, Kwon JS, Kim JJ, Youn T, Park HJ, Kim MS, et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive compulsive disorder. Acta Psychiatr Scand 2003;107:241-3.
30 Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a metaanalysis. Int Clin Psychopharmacol 1995;10:459.
31 Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998;44:1264-76.
32 Deakin JWF, Graeff FG. 5HT and mechanisms of defence. J Psychopharmacol 1991;5:305-15.
33 Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5HT in stress, anxiety and depression. Pharmacol Bioch and Behav 1996;54:129-141;
34 Hoshino K, Sugizaki M. Ulcerogenic effect of the lesion of the median raphe nucleus in fasted rats. Braz Med Biol Res 1986;19:123-30.
35 Connor KM, Davidson JRT. The role of serotonin in posttraumatic stress disorders neurobiology and pharmacotherapy. CNS spectrums 1998;3:43-51.
36 Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, Seedat S. Pharmacotherapy of postraumatic stress disorder. Cochrane Database of Systematic rewiews 2000;4:CD002795.
37 Penava SJ, Otto MW, Pollack MH, Rosenbaum JF. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety 1996-97;4:240-2.
38 Seedat S, Stein DJ, Warwick J, et al. Single photon emission computed tomography before and after treatment with the selective serotonin reuptacke inhibitor citalopram. Int J Neuropsychopharmacol 2000;2S:378.
39 Raleigh MJ, Brammer GL, McGuire MT. Male dominance, serotonergic systems, and the behavioral and physiological effects of drugs in vervet monkeys (Cercopithecus aethiops sabaeus). Prog Clin Biol Res 1983;131:185-97.
40 Mehlman PT, Higley JD, Fancher I, Lilly AA, Taub DM, Vickers J, et al. Correlation of CSE 5HIAA concentration with sociality and the timing of emigration in freeranging primates. Am J Psychiatry 1995;152:907-13.
41 Raleigh MJ, Brammer GL, McGuire MT, Yuwiler A. Dominant social status facilitates the behavioral effects of serotonergic agonists. Brain Res 1985;348:274-82.
42 Raleigh MJ, McGuire MT, Brammer GL, Yuwiler A. Social and environmental influences on blood serotonin concentrations in monkeys. Arch Gen Psychiatry 1984;41:405-10.
43 Stein MB, Delaney SM, Chartier MJ, Kroft CD, Hazen AL. [3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 1995;37:22-48.
44 Tancer ME, Mailman RB, Stein MB, Mason GA, Carson SW, Golden RN. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1994-95;1:216-23.
45 Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Clin Psychiatry 1998;59(Suppl 17):54-60.
46 van der Linden G, van Heerden B, Warwick J, Wessels C, van Kradenburg J, ZunguDirwayi N, et al. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:419-38.
47 van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a metaanalysis of randomized controlled trials. Int Clin Psychopharmacol 2000;15(Suppl 2):S15-23.
48 Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive behavioral therapy. Arch Gen Psychiatry 2002;59:425-33.